Raija K Ahmed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Raija K Ahmed has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Alimuddin Zumla
Center for Clinical Microbiology, Institute of Infection, Immunity and Transplantation, University College London, London, UK; NIHR Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK
2 shared publications - Markus Maeurer
Immunotherapy/ImmunoSurgery Laboratory, Comprehensive Cell Therapy Center (CCTC) at the Champalimaud Foundation, Avenida Brasília, Lisbon, 1400-038, Portugal.
2 shared publications - Sven Hoffner
Department of Diagnostics and Vaccines, Unit of Highly Pathogenic Microorganisms, Swedish Institute for Communicable Disease Control, S-171 82, Solna, Sweden
2 shared publications - Alena Skrahina
Republican Scientific and Practical Centre for Pulmonology and Tuberculosis, Minsk, Belarus
1 shared publication - Carol Anahelka Rodríguez
Department of Parasitology, Universidad Nacional Autónoma de Honduras, Boulevard Suyapa, Tegucigalpa 11101, Honduras
1 shared publication - Hans Gaines
The Swedish Institute for Communicable Disease Control; Stockholm, Sweden
1 shared publication
Latest Publications
- Open Access
- 6 March 2013
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 13 (1) , 1-11
Differential cellular recognition pattern to M. tuberculosis targets defined by IFN-γ and IL-17 production in blood from TB + patients from Honduras as compared to health care workers: TB and immune responses in patients from Honduras
Background: A better understanding of the quality of cellular immune responses directed against molecularly defined targets will guide the development of TB diagnostics and identification of molecularly defined, clinically relevant M.tb vaccine candidates. Methods: Recombinant proteins (n = 8) and peptide pools (n = 14) from M. tuberculosis (M.tb) targets were used to compare cellular immune responses defined by IFN-γ and IL-17 production using a Whole Blood Assay (WBA) in a cohort of 148 individuals, i.e. patients with TB + (n = 38), TB- individuals with other pulmonary diseases (n = 81) and individuals exposed to TB without evidence of clinical TB (health care workers, n = 29). Results: M.tb antigens Rv2958c (glycosyltransferase), Rv2962c (mycolyltransferase), Rv1886c (Ag85B), Rv3804c (Ag85A), and the PPE family member Rv3347c were frequently recognized, defined by IFN-γ production, in blood from healthy individuals exposed to M.tb (health care workers). A different recognition pattern was found for IL-17 production in blood from M.tb exposed individuals responding to TB10.4 (Rv0288), Ag85B (Rv1886c) and the PPE family members Rv0978c and Rv1917c. Conclusions: The pattern of immune target recognition is different in regard to IFN-γ and IL-17 production to defined molecular M.tb targets in PBMCs from individuals frequently exposed to M.tb. The data represent the first mapping of cellular immune responses against M.tb targets in TB patients from Honduras.
- 6 March 2013
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 13 (1) , 1-11
Open AccessDifferential cellular recognition pattern to M. tuberculosis targets defined by IFN-γ and IL-17 production in blood from TB + patients from Honduras as compared to health care workers: TB and immune responses in patients from Honduras
Background: A better understanding of the quality of cellular immune responses directed against molecularly defined targets will guide the development of TB diagnostics and identification of molecularly defined, clinically relevant M.tb vaccine candidates. Methods: Recombinant proteins (n = 8) and peptide pools (n = 14) from M. tuberculosis (M.tb) targets were used to compare cellular immune responses defined by IFN-γ and IL-17 production using a Whole Blood Assay (WBA) in a cohort of 148 individuals, i.e. patients with TB + (n = 38), TB- individuals with other pulmonary diseases (n = 81) and individuals exposed to TB without evidence of clinical TB (health care workers, n = 29). Results: M.tb antigens Rv2958c (glycosyltransferase), Rv2962c (mycolyltransferase), Rv1886c (Ag85B), Rv3804c (Ag85A), and the PPE family member Rv3347c were frequently recognized, defined by IFN-γ production, in blood from healthy individuals exposed to M.tb (health care workers). A different recognition pattern was found for IL-17 production in blood from M.tb exposed individuals responding to TB10.4 (Rv0288), Ag85B (Rv1886c) and the PPE family members Rv0978c and Rv1917c. Conclusions: The pattern of immune target recognition is different in regard to IFN-γ and IL-17 production to defined molecular M.tb targets in PBMCs from individuals frequently exposed to M.tb. The data represent the first mapping of cellular immune responses against M.tb targets in TB patients from Honduras.
- Open Access
- 15 February 2012
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 12 (1) , 41
Pattern recognition and cellular immune responses to novel Mycobacterium tuberculosis-antigens in individuals from Belarus
Tuberculosis (TB) is an enduring health problem worldwide and the emerging threat of multidrug resistant (MDR) TB and extensively drug resistant (XDR) TB is of particular concern. A better understanding of biomarkers associated with TB will aid to guide the development of better targets for TB diagnosis and for the development of improved TB vaccines.
- 15 February 2012
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 12 (1) , 41
Open AccessPattern recognition and cellular immune responses to novel Mycobacterium tuberculosis-antigens in individuals from Belarus
Tuberculosis (TB) is an enduring health problem worldwide and the emerging threat of multidrug resistant (MDR) TB and extensively drug resistant (XDR) TB is of particular concern. A better understanding of biomarkers associated with TB will aid to guide the development of better targets for TB diagnosis and for the development of improved TB vaccines.